RNAi modulation of MLL-AF4 and uses thereof

• US 8,034,793 B2
• Filed: 02/04/2010
• Issued: 10/11/2011
• Est. Priority Date: 12/14/2004
• Status: Active Grant

• Current Assignee: Alnylam Pharmaceuticals Incorporated
• Original Assignee: Alnylam Pharmaceuticals Incorporated
• Inventors: Heidenreich, Olaf, Hadwiger, Philipp, Vornlocher, Hans-Peter
• Primary Examiner(s): WHITEMAN, BRIAN A
• Application Number:
  US12/700,493
• Publication Number:
  US 20100256218A1
• Time in Patent Office: 614 Days
• Field of Search: 514/44
• US Class Current: 514/44.00A
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 15/1135 against oncogenes or tumor suppressor genes
• CPC Class Codes: C12N 2310/14 interfering N.A.

Abstract

The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides.

Claims

1. A method for treating a disorder associated with MLL-AF4 fusion expression comprising administering to a subject having or at risk for developing said disorder a composition comprising an iRNA agent, wherein said iRNA agent comprises a sense strand and an antisense strand and the antisense strand consists of SEQ ID NO:

15.

2. The method of claim 1, wherein said sense strand consists of SEQ ID NO:

14.

3. The method of claim 1, wherein said disorder is a proliferative disorder.

4. The method of claim 3, wherein said proliferative disorder is characterized by the presence of a t(4;

11) chromosomal translocation.

5. The method of claim 3, wherein said proliferative disorder is characterized by the presence of an MLL-AF4 fusion gene.

6. The method of claim 1, wherein said disorder is acute lymphoblastic leukemia.

7. The method of claim 1, wherein said subject is mammalian.

8. The method of claim 1, wherein the iRNA agent comprises at least one nucleotide modification.

9. The method of claim 8, wherein the nucleotide modification causes the iRNA agent to have increased stability in a biological sample.

10. The method of claim 8, wherein the nucleotide modification is a phosphorothioate or a 2′

modified nucleotide.

11. The method of claim 8, wherein the nucleotide modification is a 2′

sugar modification, a modification in a single strand overhang, a 5′

-modification which includes one or more phosphate groups or one or more analogs of phosphate groups.

12. The method of claim 8, wherein the nucleotide modification is a 5′

-uridine-adenine-3′

(5′

-UA-3′

) dinucleotide wherein the uridine is a 2′

-modified nucleotide;

a 5′

-uridineguanine-3′

(5′

-UG-3′

) dinucleotide, wherein the 5′

-uridine is a 2′

-modified nucleotide;

a 5′

-cytidine-adenine-3′

(5′

-CA-3′

) dinucleotide, wherein the 5′

-cytidine is a 2′

-modified nucleotide;

or a 5′

-uridine-uridine-3′

(5′

-UU-3′

) dinucleotide, wherein the 5′

-uridine is a 2′

-modified nucleotide.

13. The method of claim 8, wherein the nucleotide modification is a 2′

-modification chosen from the group consisting of;

2′

-deoxy, 2′

-deoxy-2′

-fluoro, 2′

-O-methyl, 2′

-O-methoxyethyl (2′

-O-MOE), 2′

-O-aminopropyl (2′

-O-AP), 2′

-O-dimethylaminoethyl (2′

-O-DMAOE), 2′

-O-dimethylaminopropyl (2′

-O-DMAP), 2′

-O-dimethylaminoethyloxyethyl (2′

-O-DMAEOE), and 2′

-O—

N-methylacetamido (2′

-O-NMA).

14. The method of claim 1, wherein the iRNA agent comprises a cholesterol moiety.

15. The method of claim 1, wherein the iRNA agent comprises at least one nucleotide overhang having 1 to 4 unpaired nucleotides.

16. The method of claim 15, wherein said nucleotide overhang is a two base overhang at the 3′

end of the antisense strand.

17. The method of claim 1, wherein said composition comprises a pharmaceutically acceptable carrier.

18. The method of claim 1, wherein said composition comprises a ligand, wherein said ligand is a lipid or lipid-based molecule.

19. The method of claim 1, wherein said iRNA agent is administered in an amount sufficient to inhibit the rate of proliferation of t(4;

11)-positive cells.

20. The method of claim 1, wherein said iRNA agent is administered at a unit dose of less than about 75 mg per kg of bodyweight or less than 200 nmole of RNA agent per kg of bodyweight.

21. The method of claim 1, wherein said iRNA agent is administered to the subject as one or more maintenance doses, ranging from 0.01 μ

g to 75 mg per kg of body weight per day.

22. The method of claim 1, wherein said method reduces MLL-AF4 fusion gene expression in a cell or tissue of said subject by at least a value selected from a group consisting of:

2%, 4%, 6%, 10%, 15%, 20% or greater.

23. The method of claim 1, wherein wildtype MLL mRNA level or wildtype AF4 mRNA level of said subject is not substantially reduced.

24. The method of claim 1, wherein said method does not trigger an interferon response.

25. The method of claim 1, wherein said method inhibits leukemic proliferation, wherein said inhibition is accompanied by an increase in apoptosis or a decrease in expression of Hoxa7, Hoxa9, and Meis-1.

26. The method of claim 1, wherein said method reduces leukemic engraftment of t(4;

11)-positive cells.

29. A method for making a pharmaceutical composition for the treatment of a proliferative disorder, comprising the step of:

1) formulating the iRNA agent of claim 1 with a pharmaceutical carrier.

30. The method of claim 29, further comprising the step of:

1) formulating the iRNA agent with a formulating agent which prolongs the half-life of the iRNA agent in human and/or mouse serum, or which facilitates uptake of the iRNA agent into cells.

27. A method for treating a proliferative disorder comprising administering to a subject a composition comprising an iRNA agent, wherein said iRNA agent comprises a sense strand and an antisense strand, the antisense strand comprising a region of complementarity to a part of mRNA encoding an MLL-AF4 fusion gene, wherein said region of complementarity is less than 30 nucleotides in length and the antisense strand comprises 15 or more contiguous nucleotides from SEQ ID NO:

15, and wherein said sense strand comprises 15 or more contiguous nucleotides of SEQ ID NO;

14.

28. The method of claim 27, wherein said MLL-AF4 fusion gene is mammalian.